Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Personalis Named to Inc.'s 2021 Best-Led Companies List

11/12/2021 | 09:04am EST

Personalis recognized in inaugural roundup for proven track record of management excellence

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that it has been named to Inc.’s inaugural 2021 Best-Led Companies list — a select, data-driven list of U.S.-based companies with the strongest management excellence and revenue of $50 million to $2 billion. Personalis was recognized for its accomplishments in four key areas including: performance and value creation; market penetration and customer engagement; talent; and leadership team.

“This inaugural list of companies represents the remarkable midsized companies, both public and private, often founder led, that are at the vanguard of reinventing American business,” said Scott Omelianuk, editor-in-chief of Inc. magazine. “With their leadership, all business will benefit from an exciting, competitive future full of possibilities.”

“We are honored to be named to the first Best-Led Companies List,” said John West, Personalis’ Chief Executive Officer. “I am proud of what the company has achieved during these challenging times. We have grown the company, increased revenue every quarter and continued to deliver new, industry-leading products to the market”.

The list recognizes 250 companies that are agile enough to maneuver but also big enough to have a broad impact. These companies employ 35 million people, about one of four U.S. workers. All 250 have a successful track record with leadership teams that spur solid performance, create value, penetrate markets, engage with customers, and more.

To compile the list, Inc. evaluated private and public U.S.-based companies using a proprietary 14-point measure of management excellence generated with input from partners at Pitchbook and Shango Labs.

To see the complete list, visit https://www.inc.com/best-led-companies/2021. The November issue of Inc. magazine is available online now at https://www.inc.com/magazine.

About Personalis

Personalis, Inc. is a leader in advanced cancer genomics for enabling the next generation of precision cancer therapies and diagnostics. The Personalis NeXT Platform® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers and clinicians with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. In population sequencing, Personalis operates one of the largest sequencing operations globally and is currently the sole sequencing provider to Veterans Affairs' Million Veteran Program. To enable cancer and population sequencing, Personalis' Clinical Laboratory was built with a focus on clinical accuracy, quality, big data, scale and efficiency. The laboratory is GxP-aligned as well as Clinical Laboratory Improvement Amendments of 1988-certified and College of American Pathologists-accredited. For more information, visit www.personalis.com and follow Personalis on LinkedIn and Twitter.

Forward-Looking Statements

All statements in this press release that are not historical are “forward-looking statements” within the meaning of U.S. securities laws, including statements relating to attributes or advantages of the Personalis NeXT Platform, Personalis’ business opportunities, leadership, plans, vision or growth, or other future events. Such forward-looking statements involve risks and uncertainties, including those related to the COVID-19 pandemic, that could cause actual results to differ materially from any anticipated results or expectations expressed or implied by such statements. Factors that could materially affect actual results can be found in Personalis’ filings with the U.S. Securities and Exchange Commission, including Personalis’ most recent reports on Forms 8-K, 10-K and 10-Q, and include those listed under the caption “Risk Factors.” Personalis disclaims any obligation to update such forward-looking statements.

ę Business Wire 2021
All news about PERSONALIS, INC.
01/20INSIDER SELL : Personalis
01/07Personalis Shares Climb Higher in Afternoon Trading Following Preliminary Revenue Repor..
01/06Personalis Expects $20.7 Million in Revenue for Q4'21
01/06PERSONALIS : Reports Preliminary Fourth Quarter and Full Year 2021 Revenue - Form 8-K
01/06Earnings Flash (PSNL) PERSONALIS Expects Q4 Revenue $20.7M
01/06Personalis Reports Preliminary Fourth Quarter and Full Year 2021 Revenue
01/06Personalis, Inc. Provides Unaudited Preliminary Revenue Guidance for the Fourth Quarter..
01/03PERSONALIS : Material Definitive Agreement - Form 8-K
01/03PERSONALIS, INC. : Entry into a Material Definitive Agreement, Financial Statements and Ex..
2021Personalis to Participate in the 24th Annual Needham Virtual Growth Conference
More news
Analyst Recommendations on PERSONALIS, INC.
More recommendations
Financials (USD)
Sales 2021 85,5 M - -
Net income 2021 -67,4 M - -
Net cash 2021 287 M - -
P/E ratio 2021 -6,64x
Yield 2021 -
Capitalization 455 M 455 M -
EV / Sales 2021 1,97x
EV / Sales 2022 3,88x
Nbr of Employees 235
Free-Float -
Duration : Period :
Personalis, Inc. Technical Analysis Chart | PSNL | US71535D1063 | MarketScreener
Technical analysis trends PERSONALIS, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 7
Last Close Price 10,17 $
Average target price 31,33 $
Spread / Average Target 208%
EPS Revisions
Managers and Directors
John S. West President, Chief Executive Officer & Director
Aaron Tachibana Chief Financial Officer
Jonathan J. MacQuitty Chairman
Richard O. Chen Chief Scientific Officer
Xavier Paliard Vice President-Immunology, Research & Development
Sector and Competitors
1st jan.Capi. (M$)
PERSONALIS, INC.-28.73%455
MODERNA, INC.-36.98%64 900
LONZA GROUP AG-15.65%52 307
IQVIA HOLDINGS INC.-14.60%46 031
SEAGEN INC.-17.50%23 323